Promotor hypermethylation of E-cadherin, p16 and estrogen receptor in prostate carcinoma.
- Author:
Qing YAO
1
;
Xiao-song HE
;
Jian-min ZHANG
;
Jie HE
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Cadherins; genetics; CpG Islands; genetics; DNA Methylation; Genes, p16; Humans; Male; Middle Aged; Polymerase Chain Reaction; Promoter Regions, Genetic; Prostatic Intraepithelial Neoplasia; genetics; metabolism; Prostatic Neoplasms; genetics; metabolism; Receptors, Estrogen; genetics
- From: National Journal of Andrology 2006;12(1):28-31
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate promotor hypermethylation of the CpG islands of E-Cadherin, p16 and estrogen receptor (ER) in prostate carcinoma and explore whether such methylation might play a role in the tumorigenesis and malignant progression of prostate carcinoma and their significance in the diagnosis, prognosis and treatment.
METHODSThirteen specimens of benign prostatic hypertrophy (BPH), 10 specimens of high grade prostate intraepithelial neoplasia (HGPIN) and 20 specimens of prostate carcinoma (with follow-up records) were collected from the patients who underwent radical prostatectomy or transurethral resection. Methylation-specific PCR (MSP) was used to detect the promoter hypermethylation of E-Cadherin, p16 and ER genes.
RESULTSHypermethylation percentages in prostate carcinoma were: E-Cadherin, 30%; p16, 25%; and ER, 65%. Almost all nonmalignant tissues (BPH and HG-PIN) lacked methylation of any genes.
CONCLUSIONDetecting promotor hypermethylation of E-Cadherin, p16 and ER may be helpful to differentiate nonmalignant lesions from prostate carcinoma.
